COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak20/08/2024
-   
  SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System20/08/2024
-   
  AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research20/08/2024
-   
  NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University20/08/2024
-   
  Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences20/08/2024
-   
  Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung20/08/2024
-   
  Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference20/08/2024
-   
  Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update20/08/2024
-   
  Entera Bio to Participate in Upcoming Investor and Scientific Conferences20/08/2024
-   
  Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 202420/08/2024
-   
  Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension20/08/2024
-   
  Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA520/08/2024
-   
  Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development20/08/2024
-   
  LAVA Reports Second Quarter 2024 Financial Results and Business Update20/08/2024
-   
  The Joint Corp. to Participate in the 7th Annual B. Riley Securities Consumer & TMT Conference20/08/2024
-   
  Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President20/08/2024
-   
  Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication20/08/2024
-   
  Algernon Pharmaceuticals Announces Closing of Private Placement20/08/2024
-   
  Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)19/08/2024
Pages